VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company says is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). The technology addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring.
The study describes a two-step process combining physical sample enrichment with bioinformatic filtering to produce greater than 99% pure ctDNA sequencing datasets. Early validation studies demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers, while additional blinded studies have produced encouraging findings. Volition said it is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications.
Volition is advancing larger validation studies, working with oncology key opinion leaders and expanding patent protection for the technology as it explores commercialization opportunities. The company is a multi-national organization focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
This publication marks a significant milestone for Volition, as it validates the technology's potential to overcome a critical barrier in liquid biopsy. The ability to isolate nearly pure tumor DNA could enable more accurate detection of cancer at earlier stages, when treatment is most effective, and improve monitoring of minimal residual disease after therapy. The substantial market opportunities cited by the company underscore the commercial potential of this innovation.
For further details, the full press release is available at https://ibn.fm/nuJEs. More information about Volition can be found on their website at https://volition.com/.
